N Am J Med Sci. 2010 Sep;2(9):403-8. doi: 10.4297/najms.2010.2408.

Whole blood viscosity assessment issues V: Prevalence in hypercreatinaemia, hyperglycaemia and hyperlipidaemia.

North American journal of medical sciences

Ezekiel Uba Nwose

PMID: 22558587 PMCID: PMC3339097 DOI: 10.4297/najms.2010.2408

Abstract

BACKGROUND: Diabetes and kidney failure are chronic diseases that are associated with cardiovascular complications, while dyslipidaemia is a strong risk factor. Hyperviscosity is believed to be associated and managed with antiplatelet, but not routinely assessed.

AIMS: This work investigates the prevalence of hyperviscosity in diabetes, dyslipidaemia and renal failure with a view to determine the proportion of patients who may not require antiplatelet therapy.

MATERIALS AND METHODS: Archived clinical pathology data for the period of 1999 to 2008 were utilized. 50,162-cases concomitantly tested for blood sugar, creatinine and lipid profile, as well as haematocrit and total proteins in five alternate years were extracted. The prevalence of different viscosity ranges associated with positive results was evaluated.

RESULTS: Hyperviscosity is about 4% prevalent in hyperglycemia and hyperlipidaemia, less in hypercreatinaemia. Hypoviscosity has statistically significantly the least <2.5% prevalent, while normoviscosity is most prevalent. Reverse analyses affirm that higher levels of hyperglycemia and hyperlipidaemia are statistically significant more associated with fourth compared to first quartile viscosity (p < 0.01).

CONCLUSION: Previous report demonstrated that hypoviscosity is synonymous to high international normalized ratio where anticoagulant/antiplatelet is not recommended. This study demonstrates that up to 97.5% of cases investigated for chronic diseases could benefit from antiplatelet medication. This report corroborates with previous reports that hyperviscosity may not be very frequent. However, the level of stasis associated with laboratory evidence-based chronic disease affirms that the subclinical vasculopathy should be managed, and laboratory monitoring will provide clinical evidence base.

Keywords: Cardiovascular complications; chronic diseases; clinical laboratory evaluation; hypercreatinaemia; hyperglycemia; hyperlipidaemia; whole blood viscosity

References

1. Free Radic Res. 2009 Oct;43(10):1008-18 - PubMed
2. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii32-5 - PubMed
3. Clin Chest Med. 2003 Mar;24(1):1-12 - PubMed
4. Prog Hemost Thromb. 1982;6:179-201 - PubMed
5. Int J Artif Organs. 2009 Jun;32(6):329-35 - PubMed
6. N Am J Med Sci. 2010 Apr;2(4):165-9 - PubMed
7. J Am Soc Nephrol. 2007 Feb;18(2):621-8 - PubMed
8. Med Princ Pract. 2008;17(1):1-13 - PubMed
9. Chest. 1992 Dec;102(6 Suppl):640S-644S - PubMed
10. Diabetologia. 1980 Oct;19(4):345-9 - PubMed
11. Acta Diabetol. 2004 Sep;41(3):99-103 - PubMed
12. Free Radic Biol Med. 2002 Jul 1;33(1):103-10 - PubMed
13. Atherosclerosis. 1999 Feb;142(2):265-8 - PubMed
14. Br J Biomed Sci. 2007;64(1):35-43 - PubMed
15. Med J Aust. 2007 May 7;186(9):461-5 - PubMed
16. N Am J Med Sci. 2009 Aug;1(3):110-3 - PubMed
17. Arch Mal Coeur Vaiss. 1995 Nov;88(11):1641-5 - PubMed
18. N Am J Med Sci. 2010 Jun;2(6):252-7 - PubMed
19. Aust N Z J Surg. 1995 Apr;65(4):267-72 - PubMed
20. N Am J Med Sci. 2010 Jul;2(7):301-5 - PubMed
21. Kidney Int. 1997 Sep;52(3):761-70 - PubMed
22. Pediatrics. 2005 Nov;116(5):1122-6 - PubMed
23. J Cardiovasc Surg (Torino). 2004 Dec;45(6):545-50 - PubMed

Publication Types

• Journal Article